Aduro Biotech launched a collaboration with Novartis to research, develop, and commercialize new immuno-oncology products, under a partnership that could generate up to $750 million for Aduro.
The companies committed themselves to developing...
It's official: Amgen is appealing last week's ruling in a fight over biosimilar Neupogen. The California-based biotech, aiming to protect its $1.2 billion branded drug, wants to bar Novartis from launching its biosimilar version, Zarxio.
Novartis CEO Joseph Jimenez presides over one of the industry's largest R&D budgets, committing about $10 billion a year to drug development. But the American-born executive, in contrast to his predecessor, has made a habit of ditching projects...
Thomson Reuters is predicting a big year for blockbuster drugs. Its analysts forecast 11 drugs approved this year will go on to rack up blockbuster sales in 2019, with new treatments from Bristol-Myers Squibb, Sanofi and Novartis leading the pack.
Cambridge, MA, biotech Semma Therapeutics is developing a stem cell technology that could help diabetics return to producing their own insulin, and the nascent company picked up $44 million and a handshake with Novartis to get rolling.
Austin, Texas, biotech Aeglea Biotherapeutics raised $44 million in Series B cash to bankroll its enzyme-replacement therapy for a rare metabolic disorder, with Eli Lilly and Novartis leading the round.
Novartis International AG / New Novartis data shows Cosentyx(TM) is
significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of
psoriasis patients . Processed and transmitted by NASDAQ OMX Corporate
Solutions. The issuer is...